X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (145) 145
chemotherapy (125) 125
humans (124) 124
index medicus (100) 100
lung neoplasms - drug therapy (81) 81
female (79) 79
antineoplastic combined chemotherapy protocols - therapeutic use (77) 77
carcinoma, non-small-cell lung - drug therapy (77) 77
aged (74) 74
middle aged (62) 62
cancer (60) 60
carboplatin (60) 60
male (60) 60
cisplatin (55) 55
gemcitabine (55) 55
lung neoplasms - pathology (52) 52
lung cancer, non-small cell (51) 51
adult (50) 50
paclitaxel (48) 48
deoxycytidine - analogs & derivatives (46) 46
deoxycytidine - administration & dosage (44) 44
carcinoma, non-small-cell lung - pathology (43) 43
care and treatment (42) 42
doublet chemotherapy (42) 42
non-small cell lung cancer (42) 42
treatment outcome (42) 42
docetaxel (39) 39
survival (38) 38
lung cancer (34) 34
open-label (34) 34
cisplatin - administration & dosage (33) 33
antineoplastic combined chemotherapy protocols - adverse effects (32) 32
neoplasm staging (30) 30
combination (29) 29
doublets (29) 29
lung neoplasms - mortality (29) 29
aged, 80 and over (27) 27
analysis (27) 27
carcinoma, non-small-cell lung - mortality (27) 27
non-small-cell lung cancer (26) 26
nsclc (26) 26
respiratory system (26) 26
disease-free survival (25) 25
research (25) 25
survival rate (23) 23
antineoplastic agents - therapeutic use (22) 22
metaanalysis (22) 22
metastasis (22) 22
1st-line treatment (21) 21
immunotherapy (21) 21
meta-analysis (21) 21
phase-iii trial (21) 21
survival analysis (21) 21
vinorelbine (21) 21
carboplatin - administration & dosage (20) 20
clinical trials (20) 20
elderly (20) 20
hematology, oncology and palliative medicine (20) 20
medicine & public health (20) 20
phase-iii (20) 20
therapy (20) 20
trial (20) 20
drug administration schedule (19) 19
paclitaxel - administration & dosage (19) 19
pharmacology & pharmacy (18) 18
prognosis (18) 18
quality-of-life (18) 18
taxoids - administration & dosage (18) 18
cancer therapies (17) 17
drug therapy (17) 17
platinum (17) 17
randomized phase-iii (17) 17
randomized-trial (17) 17
toxicity (17) 17
doublet (16) 16
multicenter (16) 16
non-small cell lung carcinoma (16) 16
patients (16) 16
randomized controlled trials as topic (16) 16
tumors (16) 16
cancer research (14) 14
deoxycytidine - adverse effects (14) 14
lung cancer, small cell (14) 14
patient outcomes (14) 14
platinum doublet (14) 14
pulmonary/respiratory (14) 14
quality of life (14) 14
vinblastine - analogs & derivatives (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
carcinoma (13) 13
clinical-trials (13) 13
efficacy (13) 13
oncology, experimental (13) 13
repeating doublet therapy (13) 13
single-agent (13) 13
vinblastine - administration & dosage (13) 13
aged patients (12) 12
bevacizumab (12) 12
breast cancer (12) 12
neoplasms. tumors. oncology. including cancer and carcinogens (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 02/2020, Volume 31, Issue 2, pp. 97 - 100
Nasopharyngeal carcinoma is a malignancy that is endemic in Asia. The current standard of care for loco-regionally advanced disease is platinum-based... 
triplet | HEAD | nasopharyngeal carcinoma | doublet | ONCOLOGY | INTENSITY-MODULATED RADIOTHERAPY | chemoradiotherapy | PHARMACOLOGY & PHARMACY | gemcitabine | cisplatin | COMBINATION | CANCER
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, pp. e0171605 - e0171605
Purpose/Objective(s) After taxane and anthracycline failure, no standard chemotherapy regimen is established in metastatic breast cancer (MBC). Capecitabine... 
MORTALITY | DOUBLET | CARCINOMA PATIENTS | PLUS CAPECITABINE | RESISTANT | ANTHRACYCLINE | MULTIDISCIPLINARY SCIENCES | PLATINUM-BASED CHEMOTHERAPY | PHASE-II | TAXANE | Multivariate Analysis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Taxoids - therapeutic use | Triple Negative Breast Neoplasms - pathology | Adult | Female | Retrospective Studies | Neutropenia - chemically induced | Bridged-Ring Compounds - therapeutic use | Gene Expression | Drug Administration Schedule | Treatment Outcome | Lymphatic Metastasis | Triple Negative Breast Neoplasms - mortality | Capecitabine - therapeutic use | Disease-Free Survival | Triple Negative Breast Neoplasms - genetics | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Anthracyclines - therapeutic use | Receptor, ErbB-2 - deficiency | Capecitabine | Patient outcomes | Breast cancer | Genetic aspects | Drug therapy, Combination | Drug therapy | Methods | Cisplatin | Medical imaging | Internal medicine | Toxicity | Oncology | Metastasis | Taxane | Multivariate analysis | Patients | ErbB-2 protein | Metastases | Medicine | Population (statistical) | Chemotherapy | Anthracycline | Medical prognosis | Breast | Cancer | Neutropenia | Tumors | Index Medicus
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 2016, Volume 17, Issue 2, pp. 91 - 99.e1
Abstract Purpose To evaluate the efficacy of 3 first-line chemotherapy combination regimens for HER2-negative metastatic breast cancer (mBC). Methods In this... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Oral vinorelbine | Taxane doublet | Capecitabine | Combination chemotherapy | Oral chemotherapy | VINORELBINE | BEVACIZUMAB | OPEN-LABEL | COMBINATION | GEMCITABINE | INTERNATIONAL CONSENSUS GUIDELINES | PACLITAXEL | NON-INFERIORITY | ONCOLOGY | CAPECITABINE PLUS DOCETAXEL | ANTHRACYCLINE-PRETREATED PATIENTS | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - chemically induced | Vinblastine - administration & dosage | Vinblastine - therapeutic use | Antimetabolites, Antineoplastic - administration & dosage | Breast Neoplasms - metabolism | Taxoids - therapeutic use | Antineoplastic Agents, Phytogenic - administration & dosage | Deoxycytidine - therapeutic use | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Administration, Oral | Deoxycytidine - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Capecitabine - therapeutic use | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Taxoids - administration & dosage | Administration, Intravenous | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Antimetabolites, Antineoplastic - adverse effects | Quality of Life | Alopecia - chemically induced | Breast Neoplasms - mortality | Aged | Deoxycytidine - analogs & derivatives | Treatment outcome | Care and treatment | Chemotherapy, Combination | Usage | Analysis | Breast cancer | Research
Journal Article
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue Supplement_4, pp. iv192 - iv237
CISPLATIN PLUS GEMCITABINE | PACLITAXEL DOUBLET CHEMOTHERAPY | ONCOLOGY | RANDOMIZED PHASE-III | MOLECULAR TESTING GUIDELINE | RESPONSE EVALUATION CRITERIA | PLATINUM-BASED CHEMOTHERAPY | WHOLE-BRAIN RADIOTHERAPY | TRANSBRONCHIAL NEEDLE ASPIRATION | QUALITY-OF-LIFE | INDIVIDUAL PATIENT DATA | Aftercare - methods | Prognosis | Precision Medicine - standards | Humans | Radiosurgery - standards | Bronchoscopy - methods | Lung Neoplasms - pathology | Tomography, X-Ray Computed | Carcinoma, Non-Small-Cell Lung - diagnosis | Lung - diagnostic imaging | Positron-Emission Tomography | Pneumonectomy - standards | Incidence | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Radiosurgery - methods | Societies, Medical - standards | Bronchoscopy - standards | Medical Oncology - methods | Lung - pathology | Brain Neoplasms - diagnosis | Europe | Aftercare - standards | Carcinoma, Non-Small-Cell Lung - epidemiology | Mutation Rate | Treatment Outcome | Lung Neoplasms - therapy | Survivorship | Magnetic Resonance Imaging | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - epidemiology | Pneumonectomy - methods | Antineoplastic Combined Chemotherapy Protocols - standards | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Brain Neoplasms - therapy | Medical Oncology - standards | Biomarkers, Tumor - genetics | Lung - surgery | Lung Neoplasms - diagnosis | Neoplasm Staging | Precision Medicine - methods | Brain Neoplasms - epidemiology
Journal Article
Lung Cancer, ISSN 0169-5002, 09/2019, Volume 135, pp. 196 - 204
•Overall survival was similar between cisplatin- and carboplatin-based chemotherapy.•Slightly greater probability of objective response for cisplatin-based... 
Carboplatin | Platinum doublet | Cisplatin | Non-small cell lung cancer | Meta-analysis | ONCOLOGY-GROUP | PHASE-III | COMBINATION | PACLITAXEL | TRIAL | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | QUALITY-OF-LIFE | GEMCITABINE PLUS CARBOPLATIN | AMERICAN SOCIETY | Chemotherapy | Analysis | Oncology, Experimental | Lung cancer, Small cell | Research | Lung cancer, Non-small cell | Pemetrexed | Cancer
Journal Article